**Meet the editor**

Berend Olivier studied biology and got his PhD degree in Neurobiology at Groningen University. He worked for 22 years at Solvay Pharmaceuticals leading active research and development of psychoactive drugs, including antidepressants, antipsychotics and anxiolytics and a new group of drugs, serenics, aiming for reduction of pathological aggression. He was involved in research

and development around fluvoxamine, a marketed SSRI antidepressant, anxiolytic and anti-OCD medicine. In 1999, he worked for 2 years in New York to set up a biotech start-up, PsychoGenics Inc., developing animal psychiatric and neurological (genetic) models in order to screen and find new psychoactive molecules. From 1992–2014, he was a professor of CNS Pharmacology at Utrecht University, performing research on animal models, brain mechanisms and pharmacology of psychiatric disorders.
